Vascular events after stroke: terutroban fails to PERFORM
2011; Elsevier BV; Volume: 377; Issue: 9782 Linguagem: Inglês
10.1016/s0140-6736(11)60708-3
ISSN1474-547X
Autores Tópico(s)Venous Thromboembolism Diagnosis and Management
ResumoAntiplatelet agents are a cornerstone in the prevention of secondary stroke, but existing drugs reduce the vascular risk by only a quarter compared with that obtained with placebo, and are associated with bleeding complications, gastrointestinal problems, and potential drug resistance. 1 Antithrombotic Trialists' CollaborationCollaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86 Crossref PubMed Google Scholar As a result, antiplatelet therapies with potentially more favourable risk–benefit ratios are actively being sought. Previous promising animal and human data have suggested that the antiplatelet activity of terutroban (an oral selective antagonist of thromboxane-prostaglandin receptors) was similar to that of aspirin, with additional beneficial pleiotropic vascular effects. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trialThe trial did not meet the predefined criteria for non-inferiority, but showed similar rates of the primary endpoint with terutroban and aspirin, without safety advantages for terutroban. In a worldwide perspective, aspirin remains the gold standard antiplatelet drug for secondary stroke prevention in view of its efficacy, tolerance, and cost. Full-Text PDF
Referência(s)